Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cisplatin 76Cetuximab 60pembrolizumab 56Radiotherapy, Intensity-Modulated 37Radiotherapy 33Carboplatin 31Docetaxel 30Fluorouracil 27Nivolumab 26Paclitaxel 20Platinum 10Albumin-Bound Paclitaxel 9Surgical Procedures, Operative 8Radiosurgery 8Radiation 8Erlotinib Hydrochloride 8durvalumab 7Bevacizumab 71,2-diaminocyclohexaneplatinum II citrate 7epacadostat 6Biopsy 6Radiotherapy, Conformal 5Ipilimumab 5Immunoglobulin G 5Gemcitabine 5Capecitabine 5130-nm albumin-bound paclitaxel 5utomilumab 4tremelimumab 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Squamous Cell Carcinoma of Head and Neck × MEDI0457 × Clear all
NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

Phase 1/2 Completed
35 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡